COLUMN: Alan, the French unicorn that proves Europe can still dream big

Impressive Growth Figures

Alan now boasts more than 1.1 million insured members across its four active markets, generating recurring annual revenue exceeding 800 million euros—an impressive 53% increase over the previous year.

Another particularly reassuring sign for investors: the company has achieved profitability in its home market of France—a pivotal milestone rarely reached so quickly by tech startups operating in a sector as heavily regulated as health insurance.

An approach focused on prevention rather than coverage alone

Unlike traditional insurers, which focus almost exclusively on reimbursing care that has already been provided, Alan takes an active prevention approach, combining digital technology, personalized support, and early detection of health issues to reduce overall costs while improving the well-being of its policyholders.

This philosophy of prevention over cure lies at the heart of the company’s value proposition—a strategic positioning that largely explains investors’ sustained enthusiasm for this distinctive business model.

This preventive approach strikes me as exactly the direction all Western healthcare systems—both public and private—should be taking: it is better to invest in early detection than to continue indefinitely funding the costly consequences of our collective neglect.

A vision born out of frustration with a system deemed outdated

The company was founded by Jean-Charles Samuelian-Werve and Charles Gorintin, two French entrepreneurs convinced that the traditional health insurance system—seen as slow, opaque, and lacking a focus on the user experience—could be completely reinvented using modern digital technology.

Their initial gamble—which might have seemed risky in such a heavily regulated sector dominated by powerful established players—has paid off over the years, transforming Alan into a leading player in European health tech.

Renowned investors, including figures from the sports world

Interestingly—and unusually in the world of health tech—the company counts French soccer players Kylian Mbappé and Antoine Griezmann among its long-standing investors; these two world-renowned sports figures have chosen to stake part of their personal fortunes on this French entrepreneurial venture.

The presence of sports personalities among the shareholders of a tech company illustrates a growing trend among elite athletes to diversify their investments into promising sectors like digital health, rather than into the traditional investments they typically favor.

I find it amusing, but also revealing, that world-renowned soccer players are choosing to invest in health insurance rather than in more glamorous assets: this may be a sign that even the wealthiest athletes are beginning to take the challenges of digital health seriously.

A Booming Sector on the Continent

The European health tech sector has been experiencing particularly strong investment momentum for several years, driven by an aging population, growing pressure on public healthcare systems, and European consumers’ increasing appetite for digital solutions to manage their own health.

This underlying trend directly benefits companies like Alan, which operate at the intersection of two traditionally conservative sectors—insurance and healthcare—while infusing them with a culture of technological innovation typical of the world’s top startups.

France: Fertile Ground Despite Regulatory Obstacles

Despite a regulatory environment often perceived as restrictive for young tech companies, France has, in recent years, produced several tech unicorns of international stature, of which Alan is now one of the most successful examples in the specific sector of digital health.

This French success is part of a broader political commitment to strengthen European technological sovereignty—a goal deemed crucial in the face of the persistent dominance of American tech giants and the rapid rise of China’s technological ambitions.

To me, every success like Alan’s represents another brick in the still-fragile edifice of European technological sovereignty: we do not need to copy the American model, but rather to forge our own path, rooted in our values and specific needs.

Four New Markets Targeted Within Eighteen Months

The funds raised in this Series G round will primarily be used to finance an ambitious international expansion, with the stated goal of launching Alan’s operations in four new countries over the next eighteen months—a particularly rapid pace of growth for a company in this highly regulated sector.

This rapid geographic expansion represents both a major growth opportunity and a significant operational challenge, as each new national market requires specific regulatory adaptation in the sensitive field of health insurance.

A Massive Investment in Artificial Intelligence

A significant portion of this new capital will also be dedicated to developing advanced artificial intelligence capabilities—a strategic priority deemed essential by Alan’s management to improve the personalization of care pathways and the platform’s overall operational efficiency.

This technological investment is part of a global race in which digital health companies are all seeking to integrate artificial intelligence to improve early diagnosis, personalized prevention, and the overall effectiveness of their services for policyholders.

The integration of artificial intelligence into digital health is no longer an option but a competitive necessity: Western companies that do not invest heavily in this area risk falling behind competitors—particularly those in Asia—who are less concerned about the ethical issues surrounding health data.

The Complexity of National Regulatory Frameworks

Alan’s international expansion inevitably faces the complexity of the regulatory frameworks specific to each European national market, as the health insurance sector remains one of the most strictly regulated across the continent, with requirements that often vary significantly from one country to another.

This regulatory fragmentation in Europe has historically been a major obstacle to the rapid growth of technology companies in the healthcare sector—a structural barrier that even a well-capitalized company like Alan will have to carefully navigate on a country-by-country basis.

The Sensitive Issue of Health Data Protection

The handling of particularly sensitive health data also imposes strict cybersecurity and privacy obligations on Alan, in accordance with the European General Data Protection Regulation (GDPR), one of the world’s most stringent legal frameworks in this area.

This rigorous European regulatory framework, although sometimes perceived as a barrier to rapid innovation, also serves as a differentiator against international competitors who are less scrupulous about these crucial issues of personal medical data confidentiality.

I believe that this European regulatory rigor regarding health data—often criticized as a barrier to innovation—could, on the contrary, become a long-term competitive advantage: consumer trust is invaluable, and Europe has the opportunity to build it better than anyone else.

A Different Approach from That of the American Giants

Unlike major U.S. health insurers, which are often criticized for the complexity of their pricing structures and what consumers perceive as a lack of transparency, Alan focuses on a streamlined user experience and direct communication with its policyholders through intuitive digital tools.

This difference in cultural and business approach partly explains why Alan’s model resonates particularly well with young companies and European workers seeking a health insurance experience that is less bureaucratic than what has historically been offered by traditional market players.

China: A Model of Technological Growth to Watch

Globally, Chinese digital health companies benefit from access to vast amounts of data and often more direct government support, which accelerates their technological development but also raises legitimate questions about the privacy of users on these platforms.

Faced with this potentially formidable Chinese competition in the medium term, Europe must continue to rely on its own tech leaders, such as Alan, which are capable of combining rapid innovation with strict adherence to Western ethical standards regarding personal data.

I remain convinced that the West must never sacrifice its ethical standards on the altar of technological speed in order to compete with China: our long-term competitive advantage lies precisely in the trust we can inspire, unlike more opaque models.

A Ripple Effect for French Startups

Alan’s continued success sends a strong positive signal to the entire French entrepreneurial ecosystem, demonstrating that it is possible to build a truly global technology company from Paris without necessarily having to relocate its headquarters to the United States to attract world-class capital.

This ripple effect could encourage more young French talent to venture into tech entrepreneurship, reassured by the tangible proof that success on the scale of Alan remains achievable from within France without requiring a systematic entrepreneurial exodus.

A Mentoring Role for the Next Generation of Entrepreneurs

Whether they explicitly acknowledge it or not, Alan’s founders now serve as informal mentors for a new generation of French entrepreneurs aspiring to build technology companies of comparable scale in other traditionally conservative sectors of the French economy.

This dynamic of informal mentoring—often underestimated in conventional economic analyses—contributes significantly to the gradual maturation of the entire French tech entrepreneurial ecosystem over the years.

I believe that the real impact of a company like Alan extends far beyond its own financial results: with every new success of this magnitude, the entire French ecosystem gains collective confidence—a psychological effect just as significant as the numbers themselves.

The Constant Pressure to Achieve Profitability on a Large Scale

Despite having already achieved profitability in its home market of France, Alan will need to demonstrate its ability to maintain this financial performance while simultaneously funding an ambitious international expansion into four new markets—a financial balancing act that is always challenging for fast-growing tech companies.

Recent history in the global tech industry is rife with examples of companies that raised substantial funds only to face major difficulties during phases of overly rapid international expansion—a precedent that calls for analytical caution even in the face of very encouraging current results.

A Valuation That Must Continue to Be Justified

A valuation of 5.5 billion euros also places Alan under constant pressure to deliver results for its investors, who will naturally expect a sustained growth trajectory that ultimately justifies a potential initial public offering (IPO) or another form of profitable financial exit for all shareholders involved.

This constant financial pressure, while manageable for such a well-capitalized company, nevertheless constitutes a risk factor that must be closely monitored in the coming years as this French unicorn—now a continental benchmark—continues to grow.

I remain cautious in the face of the media euphoria surrounding this fundraising round: an impressive valuation is never a guarantee of long-term success, and tech history is rife with examples of unicorns that failed to turn their initial promise into lasting success.

A Positive Sign for International Investors

This €480 million transaction confirms that Europe—and France in particular—remains a credible investment destination for international tech capital, despite recurring concerns about the continent’s economic competitiveness relative to the United States and Asia.

This positive signal could encourage other international investors—who have been hesitant until now—to take a closer look at investment opportunities within the European tech ecosystem, particularly in sectors with a significant societal impact, such as digital health.

A reminder that the West still has a head start

In the face of increasingly intense global technological competition, particularly from China, this type of European success serves as a reminder that the West still possesses considerable strengths: a highly skilled workforce, a reliable regulatory framework, and access to international capital that remains willing to bet on high-quality European innovation.

Alan’s success should serve as a model and inspiration for the entire Western technology ecosystem, demonstrating that it remains possible to build global champions without necessarily sacrificing the ethical and regulatory values that fundamentally distinguish our economic model from that of our main geopolitical rivals.

I see this European success as much more than just good economic news: it is a concrete argument in the broader debate over the West’s ability to remain technologically competitive without abandoning its fundamental values of transparency and the protection of citizens.

An Expansion Roadmap to Watch Closely

The coming months will be crucial for assessing Alan’s actual ability to realize its expansion ambitions in four new markets—a process that will require complex regulatory negotiations and significant operational investments in each new target territory.

Industry observers will also be closely monitoring the company’s key financial indicators, particularly its ability to maintain profitability in France during this costly international expansion phase, which is demanding in terms of both human and financial resources.

A Possible Initial Public Offering in the Medium Term

Although no official announcement has been made to that effect, Alan’s growth trajectory and current market capitalization are already fueling speculation about a possible initial public offering (IPO) in the medium term—a natural step for many tech unicorns that have reached a comparable level of maturity.

Such a move, if it were to materialize in the coming years, would mark another symbolic milestone for the French and European tech ecosystems, further strengthening the continent’s credibility as fertile ground for world-class tech companies.

I await the next chapter of this entrepreneurial journey with cautious optimism: a successful IPO for Alan would send an extremely powerful message to an entire generation of European entrepreneurs who still doubt the possibility of succeeding without leaving the continent.

An issue that goes beyond individual entrepreneurial success

Beyond Alan’s individual success, this fundraising effort is part of a broader geopolitical challenge: Europe’s ability to develop its own technology leaders in strategic sectors such as healthcare, rather than relying exclusively on solutions developed by American or Chinese companies.

This European technological sovereignty, long neglected, is gradually becoming an acknowledged political priority on a continental scale, in the face of growing geopolitical tensions that make excessive dependence on foreign technologies in sectors as sensitive as public health increasingly risky.

A Model to Be Replicated in Other Strategic Sectors

Alan’s success could inspire similar initiatives in other strategic European sectors—from defense to energy to general artificial intelligence—where Europe is actively seeking to reduce its technological dependence on foreign powers that are sometimes less aligned with its fundamental democratic values.

This broader trend toward European technological self-reliance could, if it continues at this pace, permanently reshape the global economic balance of power in the coming decades, to the benefit of a West capable of regaining some of its lost strategic autonomy.

I believe that every European technological success, such as Alan’s, is another building block in the construction of true Western sovereignty in the face of Chinese ambitions and our historical dependence on American technologies: it is a slow but essential struggle for our collective future.

A Market Neglected by Traditional Insurers

A significant portion of Alan’s customer base consists of self-employed individuals and small businesses—a market segment that has historically been underserved by major traditional French insurers, which have focused more on large corporations and their standardized group plans.

This niche strategy, developed in the company’s early years, has enabled Alan to build a loyal customer base among French self-employed individuals, who are often seeking health coverage that is more flexible and better suited to their specific professional status.

A Gradual Expansion into Large Companies

Building on this initial success with the self-employed, Alan has gradually expanded its offerings to larger companies, appealing to human resources departments seeking a more modern group health insurance experience that is better received by their employees than traditional, long-standing solutions.

This gradual diversification of its customer base is a key factor in the company’s sustained 53% growth, demonstrating the business model’s ability to adapt to different market segments without losing its original value proposition centered on simplicity and prevention.

I find this initial strategic choice to target self-employed workers neglected by major insurers particularly astute: it is often by serving overlooked markets first that the most sustainable companies build their strongest foundations.

An important milestone, but not a definitive victory

This €480 million funding round is undeniably a major milestone in the history of Alan and the broader French tech ecosystem, but it in no way guarantees the company’s future success in the face of the considerable challenges posed by rapid international expansion and increasingly intense global competition.

The true measure of Alan’s success will be determined in the coming years, based on its ability to maintain profitability while entering new markets, without ever compromising the quality of service and trust that have built its reputation among its current policyholders.

A legitimate cause for optimism for Europe’s tech sector

For now, this success deserves to be celebrated as an encouraging sign that Europe—and France in particular—retains the capacity to produce global technology leaders capable of competing with the best American and Asian companies, without abandoning the values that fundamentally distinguish our Western economic and societal model.

As the global technology race intensifies year after year, successes like Alan’s serve as a reminder that the West—and Europe in particular—still holds all the cards needed to remain a major player in global innovation for decades to come.

As I wrap up this column, I’m left with a sense of measured optimism: Alan alone won’t solve all of Europe’s technological challenges, but it proves—with hard data to back it up—that our continent retains all the capabilities needed to continue dreaming big and succeeding on a global scale.

By Maxime Marquette, columnist